Nvest Financial LLC Makes New Investment in GSK PLC Sponsored ADR $GSK

Nvest Financial LLC acquired a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 42,661 shares of the pharmaceutical company’s stock, valued at approximately $2,236,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC bought a new stake in shares of GSK in the 4th quarter worth about $528,000. AQR Capital Management LLC lifted its holdings in shares of GSK by 84.4% in the 1st quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company’s stock valued at $1,559,000 after acquiring an additional 18,420 shares during the last quarter. Empowered Funds LLC lifted its holdings in shares of GSK by 2.1% in the 1st quarter. Empowered Funds LLC now owns 79,174 shares of the pharmaceutical company’s stock valued at $3,067,000 after acquiring an additional 1,598 shares during the last quarter. Rhumbline Advisers grew its position in GSK by 20.7% in the second quarter. Rhumbline Advisers now owns 22,209 shares of the pharmaceutical company’s stock worth $853,000 after acquiring an additional 3,806 shares in the last quarter. Finally, Gabelli Funds LLC grew its position in GSK by 17.8% in the second quarter. Gabelli Funds LLC now owns 7,960 shares of the pharmaceutical company’s stock worth $306,000 after acquiring an additional 1,200 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on GSK shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of GSK in a research report on Thursday, July 30th. Jefferies Financial Group upgraded GSK to a “strong-buy” rating in a report on Friday, July 17th. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Morgan Stanley restated an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, GSK presently has a consensus rating of “Hold” and an average target price of $53.00.

GSK News Roundup

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to license exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to Hutchmed’s experimental KRAS-EGFR antibody-drug conjugate, HMPL-A830. The deal includes a reported $110 million upfront payment and could be worth up to $1.295 billion in total milestone payments, giving GSK access to a potentially differentiated solid-tumor treatment. HUTCHMED signs licensing deal with GSK for experimental solid tumour drug
• Positive Sentiment: Deutsche Bank said GSK’s Phase II mRNA flu vaccine results closely track data from Moderna’s comparable candidate. The read-through supports the credibility of GSK’s vaccine platform and could strengthen expectations for a future product in the seasonal influenza market. GSK’s mRNA flu vaccine data closely tracks Moderna’s
• Neutral Sentiment: Coverage also points to solid first-half growth and continued support from the licensing transaction. However, HMPL-A830 is an experimental, early-stage asset, so GSK must fund further development and still faces clinical, regulatory and commercial execution risks before the program can generate revenue. GSK stock gains support from licensing deal and solid first-half growth

GSK Price Performance

GSK stock opened at $49.88 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The stock has a market cap of $100.89 billion, a price-to-earnings ratio of 15.60, a price-to-earnings-growth ratio of 1.95 and a beta of 0.35. The firm has a 50-day moving average of $51.70 and a two-hundred day moving average of $53.20. GSK PLC Sponsored ADR has a 1 year low of $39.29 and a 1 year high of $61.69.

GSK (NYSE:GSK) last issued its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. During the same period last year, the company posted $0.47 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts forecast that GSK PLC Sponsored ADR will post 4.83 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.4515 per share. This represents a $1.81 annualized dividend and a yield of 3.6%. The ex-dividend date is Friday, August 14th. This is an increase from GSK’s previous quarterly dividend of $0.44. GSK’s dividend payout ratio (DPR) is 55.63%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.